패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Pulse Biosciences, Inc. 3 애널리스트 중 0 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Swayampakula Ramakanth	H.C. Wainwright & Co.
Anthony Vendetti	Maxim Group
Christopher Cooley	Stephens, Inc.

Pulse Biosciences 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Pulse Biosciences, Inc. announced delayed 10-Q filing

We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?

Companies Like Pulse Biosciences (NASDAQ:PLSE) Could Be Quite Risky

Recent updates

Executive Co-Chairman exercised options to buy US$94m worth of stock.

Executive Co-Chairman recently bought US$972k worth of stock

Pulse Biosciences, Inc. Announces Positive Clinical Data Presented At the American Thyroid Association

Pulse Biosciences, Inc. Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

Pulse Biosciences, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Pulse Biosciences, Inc. announced delayed 10-Q filing

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Pulse Biosciences, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Pulse Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell Small Cap Comp Value Index

Shelley D. Spray Does Not Stand for Reelection from the Board of Pulse Biosciences, Inc

President & CEO recently bought US$86k worth of stock

Pulse Biosciences Stock: Signs Of Life Following Q1 Update

Pulse Biosciences, Inc Announces CEO Changes

We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

New major risk - Financial position

Pulse Biosciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pulse Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Pulse Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System

Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter

Executive Chairman exercised options to buy US$382k worth of stock.

Executive Chairman recently bought US$1.1m worth of stock

Pulse Biosciences, Inc. Announces Filing of Premarket Notification 510(k) to U.S. Food and Drug Administration for its Novel CellFX nsPFA Percutaneous Electrode

Chief Strategy Officer recently bought US$105k worth of stock

Executive Chairman exercised options to buy US$68k worth of stock.

Pulse Biosciences, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Pulse Biosciences, Inc. Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

New major risk - Revenue and earnings growth

Pulse Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Executive Chairman exercised options to buy US$881k worth of stock.

Executive Chairman exercised options to buy US$36m worth of stock.

Independent Director exercised options to buy US$543k worth of stock.

Pulse Biosciences, Inc. Appoints f Gansevoort 'Gan' Dunnington, M.D. as Its Chief Medical Officer

Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?

Pulse Biosciences, Inc. Announces Resignation of Sandra Gardiner as Chief Financial Officer

Pulse Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Chief Strategy Officer & Director recently bought US$70k worth of stock

Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions

Pulse Biosciences, Inc. Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia

Pulse Biosciences, Inc. Announces Executive Changes

Pulse Biosciences appoints Kevin Danahy as CEO; Darrin Uecker to serve as CTO

Consensus revenue estimates fall by 31%

Pulse Biosciences, Inc. Receives FDA 510(K) Clearance of Expanded Energy Settings for Use with the CellFX System

Pulse Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell 2000 Dynamic Index

Pulse Biosciences, Inc. has completed a Composite Units Offering in the amount of $15 million.

Consensus forecasts updated

Price target decreased to US$11.17

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pulse Biosciences, Inc

Consensus forecasts updated

Companies Like Pulse Biosciences (NASDAQ:PLSE) Could Be Quite Risky

Pulse Biosciences, Inc., Annual General Meeting, May 19, 2022

Pulse Biosciences, Inc. to Report Q4, 2021 Results on Mar 31, 2022

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Pulse Biosciences, Inc

Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer

Pulse Biosciences, Inc Provides an Update on Recent FDA 510(k) Submission

Price target decreased to US$35.33

Price target decreased to US$35.33

Pulse Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter 2021

Forecast to breakeven in 2024

Is Pulse Biosciences (NASDAQ:PLSE) Using Debt In A Risky Way?

Consensus forecasts updated